top of page
Cancer Blog
- Dr. Robert Nagourney -
Search


The Enormous Impact of EVA/PCD Chemosensitivity Testing in Patients with Rare Cancers: Durable Benefit Provided by An Unexpected Recommendation
The drug we recommended, Pazopanib, would not normally be expected to have activity in this rare and aggressive cancer.

Dr. Robert A. Nagourney, MD
Nov 32 min read


BRCA Prostate Cancer: Lessons Learned from a Successful Outcome
On March 29, 2016, we reported the story of a 55-year-old man diagnosed 13 years earlier with prostate cancer who had failed many prior courses of therapy. When our functional profile performed on a surgical biopsy revealed an unexpected degree of activity for platinum-based chemotherapy, I decided to pursue the possibility that this patient’s tumor might carry a mutation in the BRCA genes. I referred him to a genetic counselor who conducted a genomic screen to rule out famil

Dr. Robert A. Nagourney, MD
May 15, 20162 min read
bottom of page
